StreetAlpha.app
Home › Stocks › PCRX

Pacira BioSciences, Inc. (PCRX)

Healthcare
$36.48
▲ +0.05%
LAST CLOSE · NOV 16

Pacira BioSciences sells pain treatments such as EXPAREL and ZILRETTA to patients and healthcare providers. It last closed at $36.48 on Nov 16, up 0.05% on the day. The average 12-month price target from 7 analysts is $34.57 (-5.2% from the last close), with a high of $36.50 and a low of $28.00. Analyst consensus is Hold, based on the latest ratings from 7 firms (1 buy, 6 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $7.1M, the largest $6.1M.

AI Auto Pilots
Is PCRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$743.3M
+3.7% vs a year ago
Net income
$37.7M
+76.0% vs a year ago
EPS (diluted)
$0.93
+97.9% vs a year ago
Free cash flow
$169.0M
22.7% margin
Valuation
Market cap
$1.5B
40.1M shares
P/E
39.2
Price over 12 month EPS
Price to sales
2.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$247.0M
At Sep 30
Debt
$293.6M
At Sep 30
Shareholder equity
$712.3M
Buybacks
$98.3M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $541.5M$541.5MFY2021FY2022: $666.8M$666.8MFY2022FY2023: $675.0M$675.0MFY2023FY2024: $701.0M$701.0MFY2024FY2025: $726.4M$726.4MFY2025

From PCRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
7firms
1 Buy6 Hold0 Sell
Each firm's latest rating on PCRX in the past 90 days
Average 12-month target
$34.57
▼ 5.2% downside

Based on 7 analysts who set a price target on PCRX in the past 90 days. The average target is $34.57, with a high of $36.50 and a low of $28.00, compared with the last close of $36.48.

Low $28.00Avg $34.57High $36.50
Blue marker: last close $36.48
Highest target$36.50
Average target$34.57
Lowest target$28.00
Latest rating changes
Truist SecuritiesDowngrade
Oct 9Hold$36.50
RBC CapitalTarget raised
Oct 9Hold$25 → $36.50
HC Wainwright & Co.Downgrade
Oct 9Hold$36.50
JP MorganUpgrade
Oct 8Hold$36.50
JefferiesDowngrade
Oct 8Hold$36
DateFirmActionRatingPrice target
Oct 9Truist SecuritiesDowngradeHold$36.50
Oct 9RBC CapitalTarget raisedHold$25 → $36.50
Oct 9HC Wainwright & Co.DowngradeHold$36.50
Oct 8JP MorganUpgradeHold$36.50
Oct 8JefferiesDowngradeHold$36
Loading…

Technical Analysis

PCRX · as of the Nov 16 close · updated after every close
Uptrend, overbought

The stock is 0% above its 20 day and 14% above its 50 day average. It is 29% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 83), overbought. The nearest support is the 20 day average at $36.41, and the nearest resistance the Pivot R1 at $36.49.

Short trendBullish
Long trendBullish
MomentumStrong
StretchOverbought
VolatilityLow, 0.7%/day
Key levels
$36.6752 week high+0.5%
$36.53Swing high (Nov 10)+0.1%
$36.49Pivot R1+0.0%
$36.48Pivot+0.0%
$36.48Pivot S1+0.0%
$36.48Last close
$36.4120 day average−0.2%
$36.31Swing low (Oct 22)−0.5%
$31.3950 day average−14.0%
$28.41100 day average−22.1%
$25.73200 day average−29.5%
$18.8052 week low−48.5%
Indicators
RSI (14)82.85Overbought above 70Overbought
MACD1.23Below its signal lineBearish
Stochastic64.8Middle of its rangeNeutral
ADX (14)69.4Strong uptrend
Williams %R-27.8Oversold below −80, overbought above −20Neutral
CCI (20)127.2Oversold below −100, overbought above 100Overbought
Rate of change+0.2%Change over 10 sessionsBullish
ATR (14)$0.26Typical daily range, 0.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for PCRX

What happened before

See how PCRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PCRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PCRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2011.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PCRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$7.1M
Largest print
$6.1M
Loading…

PCRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●125 buying vs 111 selling
  • ▲Held by funds +10.5 pts
  • ▲Funds holding +5
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding261256+2.0%
In funds' top 1032+50.0%
Held by funds143.3%132.8%+10.5 pts
New / increased30 / 9536 / 82+5.9%
Reduced / sold out86 / 2584 / 26+0.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PCRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PCRX is in one of them and how their past PCRX trades turned out.

PCRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PCRX in an article yet. Here's the latest on the wider market.

PCRX Congress Trades

All congress trades →
Trades, 12 months
1
Buys
1
100%
Sells
0
0%
People
1
Last filed May 14
Who traded PCRX · since 2019
Latest 5 filings of 9
$15K – $50KTraded Jan 30, 2026Filed May 14, 2026
$1K – $15KTraded May 6, 2021Filed Jun 23, 2021
$1K – $15KTraded Apr 20, 2021Filed Jun 12, 2021
$1K – $15KTraded Jan 15, 2021Filed Mar 5, 2021
$1K – $15KTraded Nov 2, 2020Filed Mar 5, 2021
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchBuy$15K – $50KJan 30, 2026May 14, 2026104 d
Tom MalinowskiD · NJBuy$1K – $15KMay 6, 2021Jun 23, 202148 d
Tom MalinowskiD · NJBuy$1K – $15KApr 20, 2021Jun 12, 202153 d
Tom MalinowskiD · NJBuy$1K – $15KJan 15, 2021Mar 5, 202149 d
Tom MalinowskiD · NJBuy$1K – $15KNov 2, 2020Mar 5, 2021123 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Pacira BioSciences

Pacira BioSciences is a pharmaceutical company based in Brisbane, California. It sells pain treatments that do not rely on opioids. Its main products are EXPAREL, a local pain treatment used around surgery that works over an extended period, ZILRETTA, a knee injection that releases medicine over time for osteoarthritis pain, and the iovera handheld device, which uses cold to block pain signals in targeted nerves. Its customers include patients and the healthcare providers who treat them.

Headquarters
Brisbane, CA